Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aptorum Group Limited - Class A Ordinary Shares (NQ: APM )

1.290 +0.050 (+4.03%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aptorum Group Limited - Class A Ordinary Shares

< Previous 1 2 3 Next >
Aptorum Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency
From Aptorum Group Limited
Via Business Wire
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 21, 2022
From Aptorum Group Limited
Via Business Wire
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2022
From Aptorum Group Limited
Via Business Wire
Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
Via ACCESSWIRE
Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong Kong
From Aptorum Group Limited
Via Business Wire
Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics
From Aptorum Group Limited
Via Business Wire
Aptorum Group Limited to Present at the H.C. Wainwright Annual Global Investment Conference, September 13-16, 2022
From Aptorum Group Limited
Via Business Wire
Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
Via ACCESSWIRE
The Global Pharmaceutical Industry is Accelerating; Aptorum Group Has Received Orphan Drug Designation from US FDA for Its SACT-1
Via ACN Newswire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property Product Safety
Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 – 26 2022
From Aptorum Group Limited
Via Business Wire
Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma
From Aptorum Group Limited
Via Business Wire
Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Business Update
From Aptorum Group Limited
Via Business Wire
First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Methods Granted
From Aptorum Group Limited
Via Business Wire
Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®
From Aptorum Group Limited
Via Business Wire
Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma
From Aptorum Group Limited
Via Business Wire
Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to Neuroblastoma
From Aptorum Group Limited
Via Business Wire
Aptorum Group Announces Updates on the Clinical Validation of its RPIDD Infectious Disease Liquid Biopsy Technology
From Aptorum Group Limited
Via Business Wire
Aptorum Group Announces the Launch of its Oncology and Autoimmune Discovery and Development Platform Targeting Unmet Mutations and Novel Biomarkers
From Aptorum Group Limited
Via Business Wire
Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma
From Aptorum Group Limited
Via Business Wire
Aptorum Group Limited Announces Results of 2021 Annual General Meeting of Shareholders
From Aptorum Group Limited
Via Business Wire
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 2, 2021
From Aptorum Group Limited
Via Business Wire
Aptorum Group Limited Interview to Air on Bloomberg U.S.
From Aptorum Group Limited
Via Business Wire
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2021
From Aptorum Group Limited
Via Business Wire
Aptorum Group Limited Has Received IND Clearance From the US FDA to Initiate Clinical Trials for Repurposed Small Molecule Drug SACT-1 for the Treatment of Neuroblastoma
From Aptorum Group Limited
Via Business Wire
Aptorum Group Announces Further Positive Interim Results of the Phase 1 Clinical Trial of ALS-4 Targeting Staphylococcus aureus
From Aptorum Group Limited
Via Business Wire
Aptorum Group Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
From Aptorum Group Limited
Via Business Wire
Aptorum Group CEO Subscribed Shares In The Company
From Aptorum Group Limited
Via Business Wire
Aptorum Group Announces Positive Interim Phase I Clinical Trial Progress for ALS-4 Targeting Staphylococcus aureus and Positive Pre-IND Progress for SACT-1 Targeting Neuroblastoma
From Aptorum Group Limited
Via Business Wire
Aptorum Group Limited to Present at The Benzinga Global Small Cap Conference
From Aptorum Group Limited
Via Business Wire
Aptorum Group Enters into an Agreement with Exeltis to Develop Aptorum’s Novel Preclinical Candidate Targeting Woman’s Gynecological Conditions
From Aptorum Group Limited
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.